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Abstract
Altered circulating microRNA (miRNA) profiles have been noted in patients with microbial infections. We compared host
serum miRNA levels in patients with hand-foot-and-mouth disease (HFMD) caused by enterovirus 71 (EV71) and
coxsackievirus 16 (CVA16) as well as in other microbial infections and in healthy individuals. Among 664 different miRNAs
analyzed using a miRNA array, 102 were up-regulated and 26 were down-regulated in sera of patients with enteroviral
infections. Expression levels of ten candidate miRNAs were further evaluated by quantitative real-time PCR assays. A receiver
operating characteristic (ROC) curve analysis revealed that six miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-
140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area
under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis
provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial
infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and
miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p,0.05). Combination of miR-545,
miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of
0.761. These data indicate that sera from patients with different subtypes of enteroviral infection express unique miRNA
profiles. Serum miRNA expression profiles may provide supplemental biomarkers for diagnosing and subtyping enteroviral
HFMD infections.
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Introduction
More than 500,000 hand-foot-and-mouth disease (HFMD)
cases including 176 fatal cases have been reported occurred in
China since March 2008 [1]. Human enterovirus 71 (EV71) and
coxsackievirus A16 (CVA16) were the two major causative agents
of HFMD accounting for more than 70% of cases in recent
outbreaks [2]. Understanding the host responses following
enteroviral infection should facilitate our understanding of
enteroviral pathogenesis and may allow the development of
diagnostic and treatment strategies. Host cellular response to
enteroviral infections is an intricate process involving a number of
molecular pathways. Genes involved in apoptosis, cellular
development and differentiation, oncogenesis, and host transcrip-
tion and translation are modified during enteroviral infections [3].
Several transcription factors such as E2F transcription factor 1,
EIF3S9, and EIF2B5, are down-regulated early in the infection
and then up-regulated later in the infection [3]. Other genes
encoding antigen presentation molecules, immune cell activation
markers, chemokines, and interferon (IFN)-inducible gene prod-
ucts are known to be modulated in response to viral infections
[3,4].
Host microRNA (miRNA) regulates cell processes by inactivat-
ing specific mRNAs via annealing to their 39 untranslated region.
Recently, miRNA has been noted to play a crucial role in the host
cellular response to viral infections [5,6]. For example, Ho and
colleagues found that induced miR-141 following enteroviral
infection contributed to down-regulation of host translation by
targeting the translation initiation factor EIF4E [7]. Our previous
study results showed that miRNAs are involved in neurological
process, immune response, and cell death pathways, playing an
important role in the host response to enteroviral infections [8].
Circulating miRNAs in serum or plasma are resistant to RNase
and have a consistent expression level among individuals infected
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27071with the same species [9]. These unique characteristics of
circulating miRNAs may provide a useful biomarker for
supplemental diagnosis and prognosis.
Aberrant circulating miRNA expression has been reported in
various non-infectious conditions [10,11] as well as in infectious
diseases such as sepsis [10,11], HBV [12,13,14], and HCV [15]. In
the present study, we evaluated serum miRNA expression levels
following enteroviral infections, and whether these changes could
be used to assist in detection these infections as well as
discrimination of specific enteroviral subtypes causing these
infections.
Materials and Methods
Research Subjects and Clinical Samples
Serum specimens included in the study were collected from
pediatric patients with HFMD and other microbial infections as
well as healthy children from May 2008 to April 2009. Healthy
subjects were the children who received regular health check and
absence of infections. Serum specimens collected from patients
with other microbial infections including Mycobacterium tuberculosis,
Bordetella pertussis, varicella-zoster virus, mumps virus, and measles
virus were also collected contemporarily. Serum specimens from
HFMD patients were collected within 72 h of the onset of clinical
symptoms. All serum samples prior to miRNA analysis were stored
at 280uC within 4 h following collection. Etiologic diagnosis of
enteroviral infections in patients was confirmed by detection of
EV71 or CVA16 from throat, stool or vesicle swab specimens
using a duplex real-time reverse-transcriptive PCR [16]. This
project was approved by the Ethics Committee of Jiangsu
Provincial Center for Diseases Prevention and Control and written
informed consent was obtained from parents or legal guardians of
all children.
Host miRNA Profiling Screening Using TaqMan Low-
Density Array
A panel of host miRNAs were assessed using TaqMan Array
Human miRNA Panel A+B (Applied Biosystems, CA), which
detects 377 functionally defined miRNAs as well as 287 miRNAs
whose function has not yet been completely defined. Total RNA
was extracted from 400 ml of 20 pooled specimens using a
mirVana PARIS kit (Ambion, Austin, TX) following the
manufacturer’s protocol for liquid samples. For miRNA amplifi-
cation and detection, 1.67 ml RNA was reverse transcribed by
using a TaqMan MiRNA Reverse Transcription Kit (Applied
Biosystems) and 2.5 ml RT products were preamplified using
Megaplex PreAmp Primers and regents. Megaplex RT reactions
were diluted 150-fold with water, and 450 ml of each diluted
product was combined with 450 ml of TaqMan 26Universal PCR
Master Mix (Applied Biosystems). One-hundred microliters of the
sample/master mix for each Megaplex pool were loaded into the
array, and the qRT-PCR was carried out on an Applied
BioSystems 7900HT thermocycler using the manufacturer’s
recommended cycling conditions. Data were analyzed with SDS
Relative Quantification Software version 2.3 (Applied BioSystems)
and the threshold cycle (CT) values equal to or greater than 40
were treated as 40. A miRNA was considered altered if CT,35 in
the one of the two groups and the miRNA showed $2-fold
differences in concentration between the patient and control
groups.
Candidate miRNA Confirmation and Quantification
Total RNA from 200 ml of individual serum was extracted
according to a method described previously [17]. Synthetic C.
elegans miRNA (cel-miR-238, Takara Biotechnology Co, Dalian,
China) was spiked-in each extracted RNA at a final concentration
of 25 fmol as an internal control. Expression levels of candidate
miRNA from the array analysis and spiked-in C. elegans miRNA
were further confirmed and quantified by using the TaqMan
miRNA Reverse Transcription Kit (Applied BioSystems). cDNA
was obtained by using miRNA-specific stem-loop primers in a
scaled down (5 ml) RT reaction (1.387 ml of water, 0.5 mlo f1 0 6
Reverse-Transcription Buffer, 0.063 ml of RNase-Inhibitor (20
units/ml), 0.05 ml of 100 mM dNTPs, 0.33 ml of Multiscribe
Reverse Transcriptase, 1 ml RT primers and 1.67 ml sample RNA.
RT reactions were performed using following conditions: 16uC for
30 min, 42uC for 30 min, 85uC for 5 min, hold at 4uC. Real time
quantitative PCR reaction was performed in a final volume of
10 ml containing 4.5 ml diluted cDNA (1:15), 5 ml TaqMan
Universal PCR Master Mix (No AmpErase) and 0.5 ml TaqMan
miRNA Assay (Applied BioSystems). The thermal cycle was set as
start with 10 min template denaturation at 95uC, 40 cycles of
denaturation at 95uC for 15 s and combined primer annealing/
elongation at 60uC for 1 min. Each serum sample for each
miRNA was run in triplicate.
Statistical Analysis
For real-time PCR assays, expression levels of miRNAs were
calculated using the CT values. Relative quantitation value of each
miRNA was calculated by using the equation 2
2DCT, in which
DCT=CTtarget miRNA-CTcel-miR-238. Then the relative quantita-
tion value of each miRNA underwent log2-transformation and
employed to show the relatively expression levels of each target
miRNAs [18,19]. Statistical analysis was performed with SPSS
software version 16.0 (SPSS, Inc., Chicago, USA). A P value,0.05
was considered statistically significant. For each miRNA, a
receiver operating characteristic (ROC) curve was generated.
Area under curve (AUC) value and 95% confidence interval (CI)
were calculated to determine the specificity and sensitivity of
enteroviral infection and subtype prediction. To increase the
diagnostic accuracy of combination of changes in plasma miRNA
levels, multiple logistic regression analysis were performed
according to methods previously described [20].
Results
During the study period, a total of 211 serum samples were
collected in which 70 were from HFMD patients, 100 from other
microbial infections, and 41 from healthy children. Among the 70
HFMD samples, 46 and 24 were confirmed to have EV 71 and
CVA16 infections, respectively. There were no significant
differences in age and gender distributions among EV71- and
CVA16-infected patients and healthy children (Table S1).
In order to identify potential candidate miRNAs whose levels
are significantly altered in response to enteroviral infection, the
TaqMan Human miRNA Low density arrays (TLDA) analysis was
performed. We screened serum miRNAs from patients with
enteroviral infections in comparison to healthy controls. Of the
664 miRNAs incorporated in the array, 126 and 151 miRNAs
were detected in serum of healthy controls and patients,
respectively. Among them, 102 were found significantly elevated
and 26 reduced in the samples from patients with specific
enteroviral infection in relation to the levels detected in healthy
controls (Table S2, details in Table S3). Ten miRNAs (miR-
148a, miR-628-3p, miR-143, miR-324-3p, miR-206, miR-545,
miR-140-5p, miR-597 miR-455-5p and miR-362-3p) that were
significantly up-regulated ($5 CT differences between the patient
and control groups) were chosen for further analysis.
MicroRNA Expression in Enterovirus Infections
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infections (M. tuberculosis, B. pertussis, varicella-zoster virus, mumps
virus, measles virus and enteroviruses) and healthy controls
revealed that most miRNAs profiles varied among different
microbial infections. The only exception is miR-140-5p, which
was altered in every microbial infection in comparison to the
healthy control (Table 1). The ten miRNAs expression profiles
were unique for enteroviruses in comparison to other microbial
infections (Table 1).
The relative levels of the ten randomly selected candidate mRNAs
in individual samples were confirmed and determined using qRT-
PCR.Serum levelsof miR-148a,miR-628-3p,miR-143, miR-324-3p,
miR-206, miR-140-5p, miR-455-5p and miR-362-3p were signifi-
cantly higher in the sera of patients with enteroviral infections than in
those from healthy controls. Expression differences of miR-545 and
miR-597 between patients and healthy controls were not statistically
significant (p.0.05) (Figure 1). ROC curves of miR-148a, miR-143,
and miR-324-3p reflected strong separation between the enteroviral
infection group and the healthy control group, with an AUC of 0.934,
0.931, and 0.901, respectively. The ROC curve of miR-628-3p, miR-
140-5p, and miR-362-3p showed moderate ability to distinguish
between the enteroviral infection group and the healthy control group,
with an AUC of 0.877, 0.847, and 0.828, respectively (Table 2).
Finally, the ROC curve of miR-206 and miR455-5p showed poor
ability to distinguish between the enteroviral infection group and the
healthy control group, with an AUC of less than 0.7 (Data not shown).
At a cut-off point set at 24.94, miR-148a yielded a sensitivity of
81.2% and a specificity of 92.9%. At a cut-off point set at 26.35, miR-
143 yielded a sensitivity of 87% and a specificity of 95.2%. At a cut-off
point set at 26.30, miR-324-3p yielded a sensitivity of 85.5% and a
specificity of 88.1% (Table 2). When expression levels of miR-148a,
miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p
were subjected to multiple logistic regression analysis, the resulting
Table 1. CT values of ten miRNA candidates in serum pool
prepared from 20 healthy controls and 20 patients with
various microbial infections assessed by TaqMan Low-Density
array.
miRNA HC EV VZV MEV MUV BP MT
miR-148a 40 30.51 29.02 31.09 30.13 28.72 40
miR-143 40 30.99 40 32.76 31.46 40 40
miR-324-3p 38.23 32.66 32.99 34.63 29.85 40 34.87
miR-628-3p 33.43 28.27 34.74 31.86 35.66 30.35 30.53
miR-140-5p 40 29.24 27.86 28.51 29.81 26.69 30.13
miR-362-3p 40 32.38 40 40 33.06 40 40
miR-206 39.95 32.11 40 40 40 32.16 34.20
miR-455-5p 40 32.20 40 33.07 40 40 40
miR-597 40 32.63 33.96 40 32.36 40 40
MiR-545 40 32.32 40 40 40 40 40
HC:Healthy control; EV:enterovirus; VZV: varicella-zoster virus; MEV: measles
virus; MUV: mumps virus; BP: Bordetella pertussis;M T :Mycobacterium
tuberculosis.
doi:10.1371/journal.pone.0027071.t001
Figure 1. Differential serum expression levels of ten miRNAs in healthy control and patients with enterovirus infection. Serum levels
of miR-140-5p, miR-143, miR-148a, miR-362-3p, miR-455-5p, miR-324-3p, miR-206, and miR-628-3p except for miR-545 and miR-597 were significantly
higher in patients with enterovirus infection than those in the control group. **, p,0.01.
doi:10.1371/journal.pone.0027071.g001
MicroRNA Expression in Enterovirus Infections
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distinguishing enteroviral patients from healthy controls (Figure 2).
At a cut-off point set at 216.15, this combination yielded a sensitivity
of 97.1% and a specificity of 92.7%. The expression profile in
combination of six miRNAs represented a unique fingerprint that
differentiated enterovirial infections from other microbial infections.
To explore whether serum miRNA expression levels can
differentiate enteroviral subtypes, the expression levels of above
10 miRNAs were further contrasted in patients infected with
EV71 and CVA16. Five miRNAs including miR-148a, miR-143,
miR-324-3p, miR-545, and miR-140-5p showed significantly
higher expression in the CVA16 group when compared with the
EV71 group (Figure 3). ROC curve analyses revealed that the
serum levels of miR-545, miR-324-3p, and miR-143 showed
moderate ability to differentiate patients with CVA16 infection
from those with EV71 infection, with an AUC of 0.727 (95%
CI=0.594–0.860), 0.723 (95% CI=0.603–0.843), and 0.712
(95% CI=0.592–0.832). The ROC curve of miR-148a and
miR-140-5p showed poor ability to distinguish between infection
with CVA16 and infection with EV71, with an AUC of less than
0.7 (Data not shown). The AUC was slightly increased to 0.761
(95% CI=0.644–0.879) by combining the above 3 miRNAs as
described above (Figure 4). At the optimal cutoff value of 0.296,
the sensitivity and specificity was 0.792 and 0.652, respectively.
Discussion
Various laboratory methods have been developed to diagnose
enteroviral infections. Isolation of virus followed by immuno-
staining with specific monoclonal antibodies is time consuming
and labor intensive. Serological diagnosis, which is based on a
fourfold rise of antibody titer, generally takes 10–14 days after
the onset of illness. Reverse-transcriptive PCR techniques, which
target the enterovirus 59 conserved un-transcribed region, have
become widely used in the laboratory diagnosis of enteroviral
infections [16]. However, sub-optimally designed primer sets and
inappropriate PCR procedures may result in false-negative
results by missing certain enteroviral subtypes and mutants as
well as false-positive results due to cross reactions with
rhinovirueses.
The most commonly used molecular diagnostic methods for
viral infections, such as RT-PCR, dependent on the genetic
sequence of specific pathogens. The mutation of the virus gene
may result in false negative results. Recently host responsive
circulating miRNAs have been intensively studied as a new
noninvasive marker for both diagnosis and prognosis. Most
published studies have been focused on different types of cancer
[10,11]. Other studies have demonstrated dysregulated serum/
plasma miRNA expression in non-cancerous processes such as
oxidative liver injury, pregnancy, heart disease, diabetes, and
tissue injuries [19,21,22,23,24,25,26,27,28,29]. More recently, the
role of miRNA in pathogen-host infectious interactions has been
highlighted. Human miRNAs have important functions in viral
replication and may be used by host cells to control viral infection.
Virus encoded miRNAs appear to function in controlling viral
replication, limiting antiviral responses, inhibiting apoptosis, and
stimulating cellular growth [30]. Therefore, it is not surprising to
find that host cell miRNA expression are altered after various
pathogen infections [8,31,32,33,34,35]. Consistent with those
observations, aberrant serum/plasma miRNA expression also
have been found in patients with various microbial infections
[10,11,12,13,14,15]. These results supported the concept that
expression alteration of circulating miRNAs can be associated with
a specific patho(physiological) state [24,36].
In this study, we investigated expression levels of a panel of host
miRNA in patients with enteroviral infections and in healthy
controls. By the two-step screening and confirmation approach, we
identified eight miRNA which were significantly up-regulated (CT
value difference $5) in patients in comparison to controls. To
evaluate the efficiency of these dysregulated miRNAs for
diagnosing and subtyping enteroviral infections, ROC curves
were constructed for each miRNA. Expression levels of six
miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-
140-5p, and miR-362-3p) showed good ability to efficiently
distinguish enteroviral infections from other microbial infections,
with AUCs that ranged from 0.828 to 0.934. However, there was
no single candidate miRNAs to distinguish enterovirial infections
from other microbial infection and healthy controls. For example,
expression of miR-140-5p was up-regulated in all detected
microbial infections. A profile consisted of multiple host miRNA
profiles is needed to well represent unique characteristics of each
microbial infection. In our study, combination of six selected host
miRNAs not only created a unique profile for enterovirial
infections but also significantly increased the diagnosis efficiency
with AUC of 0.989.
Figure 2. Receiver operating characteristic (ROC) curve for
expression changed miRNAs to distinguish enterovirus infec-
tion from healthy control. Combination of miR-148a, miR-143, miR-
324-3p, miR-628-3p, miR-130-5p, and miR-362-3p showed stronger
distinguish efficiency. The AUC of 0.989 was obtained by combining
above six miRNAs.
doi:10.1371/journal.pone.0027071.g002
Table 2. Areas under the receiver operating characteristic
curve (AUC) and predictive value of six candidate miRNAs.
miRNA AUC 95% CI
cut-off
point
Sensitivity
(%)
Specificity
(%)
miR-148a 0.934 0.886–0.982 24.94 81.2 92.9
miR-143 0.931 0.882–0.979 26.35 87.0 95.2
miR-324-3p 0.901 0.838–0.964 26.30 85.5 88.1
miR-628-3p 0.877 0.813–0.941 28.66 73.9 92.9
miR-140-5p 0.847 0.773–0.920 26.06 72.5 88.1
miR-362-3p 0.828 0.751–0.905 212.07 81.2 81.0
doi:10.1371/journal.pone.0027071.t002
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CAV16 are indistinguishable. However, it has been reported that
EV71 is more likely than CAV16 to cause severe/fatal
neurological diseases such as aseptic meningitis or encephalitis
[37]. Early and rapid differentiation of enterovirus subtypes may
benefit disease management and allow improved prognosis
prediction. We found five miRNAs (miR-148a, miR-143, miR-
324-3p, miR-545, and miR-140-5p) showed significantly higher
expression in patients with CVA16 infection compared with those
with EV71 infection. One noticeable finding of the present study
was that combination of expression levels of three miRNAs (miR-
545, miR-324-3p, and miR-143) provided moderate ability to
differentiate between EV71 and CVA16 infections. Li and
colleagues reported that a group of serum miRNAs accurately
discriminated HBV cases from HCV cases despite identical
clinical manifestations of hepatitis for both HBV and HCV
infections [13]. While definitive diagnosis depends on organism-
specific detection methods, our data suggested that host miRNA
prolifes provide a supplemental biomarker for enteroviral
differential diagnosis and genotyping at an early stage of
infection. An extended study is being designed to enroll
additional HFMD patient having a variety of enteroviral subtype
infections; additional relevant host miRNA molecules will be
investigated.
Supporting Information
Table S1 Demographic data of HFMD patients and
healthy controls.
(DOC)
Figure 3. Differential serum expression levels of ten miRNAs in EV71 group and CVA16 group. Serum levels of miR-148a, miR-143, miR-
324-3p, miR-545, miR-140-5p, were significantly higher in CVA16 group than those in the EV71 group. *, p,0.05. **, p,0.01.
doi:10.1371/journal.pone.0027071.g003
Figure 4. Receiver operating characteristic (ROC) curve for
expression changed miRNAs to distinguish CVA16 infection
from EV71 infection. ROC curve of miR-545 (A), miR-324-3p (B), and
miR-143 (C) showed moderate distinguish efficiency. The AUC was mild
increased to 0.761 through combining above three miRNAs (D).
doi:10.1371/journal.pone.0027071.g004
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